Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07594223

Efficacy of Activator Trigger Point and Shock Wave Therapy on Pain and Function in Active Upper Trapezius Trigger Points: A Randomized Controlled Study

This study will be conducted as a randomized controlled trial to evaluate the efficacy of trigger point activator and extracorporeal shock wave therapy in patients with active myofascial trigger points in the upper fibers of the trapezius muscle. Participants who meet the inclusion criteria will be recruited and informed consent will be obtained prior to participation. The subjects will then be randomly allocated into two equal groups. Group A: will receive treatment using the trigger point activator applied to the active trigger points of the upper trapezius muscle. Group B: will receive extracorporeal shock wave therapy applied to the same region.

The treatment will be applied according to standardized therapeutic parameters for a predetermined number of sessions over the study period. Outcome measures will be assessed before the beginning of the treatment program and after completion of the intervention period. Pain intensity and pressure pain threshold will be assessed using an algometer. Functional disability related to the neck will be evaluated using the Neck Disability Index (NDI). All collected data will be recorded and statistically analyzed to determine the effectiveness of both treatment modalities in reducing pain and improving functional outcomes.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

27 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This study will be conducted as a randomized controlled trial to evaluate the efficacy of trigger point activator and extracorporeal shock wave therapy in patients with active myofascial trigger points in the upper fibers of the trapezius muscle. Participants who meet the inclusion criteria will be recruited and informed consent will be obtained prior to participation. The subjects will then be randomly allocated into two equal groups. Group A: will receive treatment using the trigger point activator applied to the active trigger points of the upper trapezius muscle. Group B: will receive extracorporeal shock wave therapy applied to the same region.

The treatment will be applied according to standardized therapeutic parameters for a predetermined number of sessions over the study period. Outcome measures will be assessed before the beginning of the treatment program and after completion of the intervention period. Pain intensity and pressure pain threshold will be assessed using an algometer. Functional disability related to the neck will be evaluated using the Neck Disability Index (NDI). All collected data will be recorded and statistically analyzed to determine the effectiveness of both treatment modalities in reducing pain and improving functional outcomes. 15. Participants of the study:

  • The number of participants: 200 (50 per group to ensure 40 completers per arm after attrition).
  • Important characteristics
  • Adult (27:40 years):
  • Gender: both gender
  • Diagnosis: Active upper trapezius trigger points Inclusion criteria
  • Male or female participants aged between 25 and 40 years.
  • Body Mass Index (BMI) between 20 and 30 kg/m².
  • Presence of active myofascial trigger points in the upper fibers of the trapezius muscle confirmed by clinical examination.
  • Complaints of neck pain associated with upper trapezius trigger points.
  • Ability and willingness to participate in the treatment sessions and follow the study protocol.

Exclusion criteria

  • History of neck trauma, cervical spine fracture, or cervical spine surgery.
  • Presence of neurological disorders affecting the cervical region.
  • Presence of cervical disc prolapse or severe cervical spine pathology.
  • Diagnosis of fibromyalgia or systemic musculoskeletal disorders.
  • Presence of skin diseases, wounds, or infections at the treatment area.
  • Patients with malignancy or severe systemic diseases.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Male or female participants aged between 25 and 40 years. 2. Body Mass Index (BMI) between 20 and 30 kg/m². 3.Presence of active myofascial trigger points in the upper fibers of the trapezius muscle confirmed by clinical examination.
  • Complaints of neck pain associated with upper trapezius trigger points. 5. Ability and willingness to participate in the treatment sessions and follow the study protocol.

Exclusion criteria

  • 1. History of neck trauma, cervical spine fracture, or cervical spine surgery. 2. Presence of neurological disorders affecting the cervical region. 3. Presence of cervical disc prolapse or severe cervical spine pathology. 4. Diagnosis of fibromyalgia or systemic musculoskeletal disorders. 5. Presence of skin diseases, wounds, or infections at the treatment area. 6. Patients with malignancy or severe systemic diseases.

Treatment and study plan

Shockwave

Device

will receive extracorporeal shock wave therapy applied to the same region. 12. The treatment will be applied according to standardized therapeutic parameters for a predetermined number of sessions over the study period.

Activator

Device

will receive treatment using the trigger point activator applied to the active trigger points of the upper trapezius muscle.

Primary outcomes

  1. Neck Disability Index (NDI)

    Time frame: 6 weeks

    Questionnaire assessing neck function valid and reilable

  2. VAS

    Time frame: 6 weeks

    Pain score

Study contacts

Contact information is provided by the study sponsor or research team.

Mina Wahba, phD

CONTACT

[email protected]

+062 3707068

Sponsors and collaborators

Lead sponsor

Cairo University

Other

Collaborators

  • Suez University

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 18, 2026
Registry last updated
May 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.